AltPep’s technology is based on decades of research and discoveries from the Daggett Research Group, culminating in technology that targets a fundamental toxic protein structure formed during amyloidogenesis. By developing and employing innovative computer modeling techniques, they discovered a new protein structure (alpha-sheet) linked to the toxic misfolded aggregates — believed to be the underlying cause of over 50 human amyloid diseases, including Alzheimer’s Disease, Parkinson’s Disease, type-2 diabetes, and biofilm-associated multidrug-resistant infections. Their proprietary platform targets these toxic species for both early diagnostics and disease-modifying therapeutics.

AltPep Corporation Website